intern
societi
influenza
respiratori
viru
diseas
isirv
held
antivir
group
confer
univers
texa
june
emerg
resist
drug
current
licens
treatment
prophylaxi
influenza
virus
primarili
neuraminidas
inhibitor
oseltamivir
phosphat
tamiflu
inhibitor
amantadin
rimantadin
lack
effect
intervent
respiratori
virus
programm
focus
discoveri
develop
inhibitor
sever
viru
target
key
host
cell
factor
involv
viru
replic
mediat
inflammatori
respons
viru
target
includ
influenza
haemagglutinin
neuraminidas
protein
respiratori
syncyti
viru
influenza
polymeras
nucleoprotein
therapi
rhinovirus
mer
sar
coronavirus
also
discuss
emerg
develop
monoclon
antibodi
therapeut
potenti
implic
antibodydepend
enhanc
diseas
also
address
topic
cover
aspect
structur
molecular
biolog
preclin
clinic
studi
import
suitabl
clinic
trial
endpoint
regulatori
issu
also
discuss
perspect
industri
govern
meet
summari
provid
overview
confer
particip
also
interest
current
statu
antivir
respiratori
virus
intern
societi
influenza
respiratori
viru
diseas
isirv
independ
intern
scientif
profession
societi
promot
prevent
detect
treatment
control
influenza
respiratori
viru
diseas
isirv
antivir
group
isirvavg
establish
follow
merger
april
former
neuraminidas
inhibitor
suscept
network
nisn
isirv
group
aim
promot
understand
mean
prevent
treatment
control
influenza
respiratori
viru
diseas
includ
emerg
antivir
resist
commun
preclin
clinic
develop
potenti
novelnew
antivir
three
meet
held
annual
differ
region
world
isirv
antivir
group
confer
held
univers
texa
june
emerg
resist
drug
current
licens
treatment
prophylaxi
influenza
primarili
neuraminidas
inhibitor
nai
oseltamivir
phosphat
tamiflu
inhibitor
amantadin
rimantadin
lack
effect
intervent
respiratori
virus
programm
focus
discoveri
develop
inhibitor
sever
viru
target
key
host
cell
factor
involv
viru
replic
mediat
inflammatori
respons
viru
target
includ
influenza
haemagglutinin
neuraminidas
protein
respiratori
syncyti
viru
rsv
influenza
polymeras
nucleoprotein
therapi
rhinovirus
middl
eastern
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
coronavirus
sarscov
also
discuss
emerg
develop
monoclon
antibodi
therapeut
potenti
implic
antibodydepend
enhanc
diseas
also
address
topic
cover
aspect
structur
molecular
biolog
preclin
clinic
studi
import
suitabl
clinic
trial
endpoint
regulatori
issu
also
discuss
perspect
industri
govern
meet
summari
provid
overview
confer
particip
also
interest
current
statu
antivir
respiratori
virus
nanci
cox
center
diseas
control
prevent
atlanta
usa
prior
licens
nai
aminoadamantan
drug
use
treatment
prevent
influenza
target
viru
ion
channel
protein
involv
viru
uncoat
endosom
see
howev
due
central
nervou
system
complic
elderli
lack
efficaci
influenza
b
wide
employ
addit
sinc
mani
virus
acquir
mutat
gene
confer
resist
includ
current
human
virus
avian
influenza
virus
caus
sporad
human
infect
resist
initi
emerg
china
possibl
relat
readi
avail
aminoadamantan
counter
medic
use
poultri
feed
nai
tamiflu
prodrug
oseltamivir
phosphat
taken
oral
capsul
relenza
zanamivir
inhal
powder
approv
recent
peramivir
rapivab
administ
intraven
well
longact
deriv
zanamivir
laninamivir
inavir
approv
countri
us
cdc
recommend
use
nai
patient
suspect
confirm
influenza
hospitalis
high
risk
complic
due
influenza
includ
patient
less
year
age
underli
medic
condit
compromis
immun
pregnant
women
cdc
clinician
advis
use
clinic
judgement
guid
nai
treatment
outpati
high
risk
one
studi
show
antivir
underprescrib
highrisk
outpati
receiv
prescript
present
less
h
post
symptom
onset
haver
et
al
furthermor
laboratoryconfirm
influenza
outpati
given
antivir
prescript
versu
prescrib
antibiot
recent
emerg
novel
influenza
circul
poultri
usa
cdc
recommend
antivir
treatment
soon
possibl
hospitalis
patient
novel
influenza
virus
associ
sever
infect
influenza
vaccin
still
recommend
mean
primari
protect
cdc
new
human
strain
emerg
antigen
distinct
vaccin
compon
interim
vaccin
effect
viru
infect
estim
januari
flanneri
et
al
new
viru
result
highest
number
hospit
usa
sinc
record
began
year
ago
thu
cdc
focus
commun
remind
clinician
recommend
nai
use
regardless
vaccin
statu
recent
controversi
efficaci
nai
cochran
group
carri
metaanalysi
clinic
data
oseltamivir
zanamivir
trial
enrol
outpati
uncompl
influenza
conclud
oseltamivir
provid
h
benefit
adult
h
benefit
children
zanamivir
day
benefit
among
enrol
particip
regardless
influenza
infect
intent
treat
itt
popul
jefferson
et
al
fail
find
signific
decreas
number
hospit
treatment
conclud
increas
risk
nausea
oseltamivir
possibl
psychosi
harm
treatment
outweigh
benefit
howev
pride
studi
muthuri
et
al
use
metaanalysi
global
hospit
individu
patient
observ
studi
show
nai
treatment
led
decreas
mortal
adult
earli
treatment
reduct
mortal
signific
benefit
observ
children
recent
multi
parti
group
advic
scienc
muga
repeat
metaanalysi
randomis
placebocontrol
clinic
trial
oseltamivir
enrol
outpati
adult
use
individu
level
patient
data
demonstr
day
decreas
time
allevi
symptom
reduct
antibiot
prescript
decreas
hospit
itt
influenzainfect
popul
dobson
et
al
new
antivir
need
face
higher
benchmark
prove
efficaci
includ
demonstr
reduct
sever
complic
due
influenza
recent
mistrust
studi
fund
industri
lead
higher
cost
clinic
trial
ultim
drug
dilemma
pay
fred
hayden
univers
virginia
usa
recent
clinic
trial
disappoint
inhal
longact
deriv
zanamivir
laninamivir
uncompl
influenza
intraven
peramivir
hospitalis
patient
fail
meet
primari
clinic
endpoint
allevi
symptom
normal
vital
sign
addit
sialidas
fusion
protein
act
remov
potenti
sialic
acid
receptor
influenza
belser
et
al
show
decreas
viru
load
uncompl
influenza
signific
clinic
benefit
moss
et
al
combin
therapi
mostli
nai
drug
differ
target
hayden
current
evalu
tri
increas
potenc
reduc
likelihood
oseltamivir
resist
also
test
parainfluenza
piv
virus
also
use
sialic
acid
receptor
jone
et
al
rhinovirus
pleconaril
capsid
bind
inhibitor
result
decreas
total
symptom
sever
broadli
effect
multipl
differ
strain
viru
newer
deriv
vapendivir
test
adult
rhinoviru
infect
asthma
clinicaltrialsgov
mani
inhibitor
discuss
detail
subsequ
program
influenza
keynot
lectur
structur
mechan
drug
target
influenza
polymeras
stephen
cusack
embl
grenobl
franc
influenza
rnadepend
rna
polymeras
good
drug
target
sinc
activ
site
highli
conserv
polymeras
complex
compos
three
protein
pa
essenti
transcript
gener
cap
viral
mrna
replic
gener
full
length
vrna
genom
incorpor
new
virion
antigenom
crna
provid
templat
full
length
vrna
bind
host
cell
premrna
associ
cell
pol
ii
short
cap
rna
fragment
cleav
pa
endonucleas
process
known
cap
snatch
transcript
elong
initi
use
cap
primer
earli
attempt
crystal
solubl
fragment
limit
success
howev
recent
express
complet
trimer
polymeras
use
selfcleav
polyprotein
novel
bat
influenza
viru
influenza
b
enabl
solv
xray
crystal
structur
complex
rna
promot
compris
nucleotid
end
vrna
resolut
reich
et
al
structur
suggest
capbind
domain
rotat
first
allow
endonucleas
cleav
host
premrna
altern
configur
cap
oligom
enter
polymeras
activ
site
prime
transcript
three
subunit
thu
involv
rna
bind
transcript
influenza
b
polymeras
complex
vrna
yield
differ
structur
complex
vrna
may
repres
altern
conform
activ
cap
snatch
la
cross
bunyaviru
rna
segment
singl
l
polymeras
protein
similar
total
size
influenza
complex
structur
analysi
show
similar
overal
architectur
domain
structur
influenza
enzym
despit
diverg
gerlach
et
al
structureguid
drug
design
use
develop
inhibitor
cap
snatch
subunit
pa
endonucleas
kowalinski
et
al
pautu
et
al
pa
inhibitor
chelat
two
critic
manganes
ion
activ
site
enzym
savira
esrf
spin
roch
undertak
develop
polymeras
inhibitor
resist
studi
vitro
shown
passag
viru
presenc
endonucleas
inhibitor
chang
ic
lorant
leopold
janssen
pharma
titusvil
usa
nonnucleosid
inhibitor
target
byrn
et
al
clark
et
al
inhibit
product
viral
mrna
prevent
death
infect
cell
unlik
nai
still
allow
cell
death
effect
influenza
strain
test
cell
cultur
includ
resist
nai
also
effect
reduc
mortal
lethal
mous
model
mgkg
result
decreas
mortal
due
apuerto
infect
mice
mgkg
could
deliv
h
postinfect
still
lead
decreas
mortal
synergi
demonstr
combin
oseltamivir
zanamivir
favipiravir
vitro
mgkg
alon
protect
mice
synergist
effect
oseltamivir
lead
surviv
human
challeng
studi
differ
dose
test
includ
mg
daili
day
load
dose
mg
first
day
follow
mg
daili
day
primari
endpoint
area
curv
viru
shed
determin
viru
infect
cell
cultur
qrtpcr
statist
signific
decreas
viru
shed
seen
cohort
although
durat
viru
shed
affect
also
dosedepend
decreas
symptom
score
durat
symptom
resist
screen
reveal
mutat
gene
four
patient
result
reduct
sensit
howev
mutant
virus
reduc
fit
estim
wild
type
cusack
comment
resist
seen
within
passag
vitro
mutat
phenylalanin
involv
tight
bind
inhibitor
influenza
serin
lead
resist
lack
phenylalanin
influenza
b
account
part
natur
poor
bind
lack
activ
influenza
b
phase
trial
evalu
dose
rang
versu
twice
daili
dose
healthi
patient
anni
slamaschwok
inra
jouy
en
josa
franc
influenza
ribonucleoprotein
rnp
complex
compos
three
subunit
polymeras
associ
viral
rna
genom
cover
multipl
copi
nucleoprotein
np
np
highli
conserv
protein
thu
potenti
good
target
broadlyreact
antivir
recent
structur
polymeras
complex
cryoelectron
microscopi
studi
rnp
provid
basi
silico
screen
sigma
catalogu
inhibitor
nppolymeras
nprna
interact
naproxen
known
antiinflammatori
inhibit
cellular
cylcooxygenas
identifi
competitor
nperna
interact
protect
np
cterminu
proteolysi
naproxen
reduc
infect
virus
cell
ec
mm
mgkg
per
day
decreas
viru
titer
mice
lejal
et
al
two
deriv
synthesis
specif
viral
rnp
naproxen
co
taru
et
al
naproxen
co
compet
rna
bind
np
destabil
nprna
oligom
stabil
monomer
np
potent
ic
mm
solubl
less
toxic
naproxen
longer
inhibit
human
cell
work
antiinflammatori
compound
target
nadph
oxidas
nox
aim
dual
antivir
antiinflammatori
approach
identif
character
influenza
variant
resist
viral
endonucleas
inhibitor
gyanendra
kumar
st
jude
children
research
hospit
memphi
usa
diketo
acid
inhibitor
influenza
viru
polymeras
pa
subunit
stevaert
et
al
stevaert
et
al
previous
describ
mutat
confer
reduc
sensit
stevaert
et
al
kumar
carri
random
mutagenesi
natur
mutant
emerg
passag
cell
cultur
gener
plasmid
librari
use
revers
genet
gener
recombin
virus
passag
inhibitor
passag
potenti
resist
virus
select
mutat
includ
also
seen
stevaert
et
al
mutat
margin
reduc
polymeras
activ
virus
appear
lose
fit
similar
growth
properti
vitro
similar
weight
loss
viru
titer
mld
mice
joseph
baumann
rutger
univers
usa
crystal
ntermin
domain
endonucleas
pa
viru
use
fragment
screen
identifi
new
chemic
entiti
bind
enzym
activ
site
scaffold
shown
bind
site
identifi
new
mode
chelat
activ
site
metal
ion
bauman
et
al
third
mn
ion
previous
identifi
also
detect
sar
studi
led
improv
bind
reduc
ic
mm
nm
fluoresc
base
enzym
assay
mm
plaqu
reduct
assay
pra
ic
enzym
assay
vari
depend
whether
mg
mn
reaction
activ
compound
ic
mm
pra
clinic
antiinfluenza
viru
effect
favipiravir
novel
antirna
viru
antiinfluenza
agent
carol
epstein
medivector
inc
boston
usa
favipiravir
select
inhibitor
rnadepend
rna
polymeras
influenza
viru
also
report
inhibit
broad
rang
rna
virus
furuta
et
al
oestereich
et
al
addit
sinc
target
na
effect
oseltamivirresist
virus
tarbet
et
al
patient
studi
clinic
trial
evalu
symptom
improv
emerg
resist
first
phase
trial
patient
season
signific
benefit
observ
second
phase
trial
evalu
twice
bid
versu
three
time
tid
daili
administr
differ
dose
mg
tid
day
mg
tid
day
mg
load
dose
two
mg
dose
day
follow
mg
tid
day
bid
day
mg
bid
day
higher
load
dose
need
maintain
c
min
level
mgml
bid
tid
group
show
rapid
decreas
viru
titer
compar
placebo
group
interestingli
bid
group
show
statist
signific
decreas
time
resolut
symptom
tid
among
individu
symptom
statist
signific
decreas
demonstr
symptom
fever
resist
detect
clinic
sampl
test
far
sampl
test
phase
multicountri
trial
recent
conclud
enrol
discoveri
develop
nucleosid
analogu
inhibitor
rsv
rna
polymeras
julian
symon
alio
biopharma
inc
san
francisco
usa
rsv
l
protein
viral
rnadepend
rna
polymeras
contain
multipl
enzym
activ
requir
rsv
replic
use
cell
base
screen
assay
novel
cytidinebas
analogu
oral
avail
prodrug
identifi
potent
specif
inhibitor
replic
laboratori
clinic
strain
rsv
b
deval
et
al
ec
approxim
nm
k
nm
enzym
f
clch
group
contribut
select
vitro
inhibitor
caus
chain
termin
viral
rna
synthesi
inhibit
cellular
unrel
viru
rna
polymeras
also
inhibit
relat
paramyxovirus
includ
human
metapneumoviru
parainfluenza
viru
high
level
form
primari
epitheli
cell
oral
administr
nonhuman
primat
result
high
level
ntp
lung
halflif
h
human
challeng
studi
adult
volunt
administ
either
high
load
dose
mg
follow
mainten
dose
mg
constant
dose
mg
placebo
group
quantit
rtpcr
peak
rsv
rna
titer
around
log
day
post
challeng
mg
mg
group
immedi
decreas
rsv
rna
level
decreas
symptom
score
mucu
weight
mg
group
initi
increas
viru
rna
follow
decreas
thu
indic
import
high
load
dose
well
toler
resist
viru
isol
although
vitro
passag
mutat
found
activ
site
l
protein
current
undergo
evalu
hospitalis
infant
qin
yu
astrazeneca
r
boston
waltham
usa
polymeras
inhibitor
tiongyip
et
al
activ
rsv
averag
ec
nm
b
averag
ec
mm
subtyp
mani
cell
line
effect
ad
h
post
infect
detect
cytotox
mm
inhibit
earli
stage
mrna
transcript
well
genom
replic
inhibit
initi
rna
synthesi
promot
noton
et
al
resist
virus
isol
passag
cultur
domin
mutat
put
cap
enzym
domain
l
protein
result
greater
increas
ec
rsv
nucleoprotein
n
essenti
viru
replic
assembl
part
viral
rnp
complex
previous
benzodiazepin
report
inhibit
rsv
rna
synthesi
infect
releas
viru
ec
approxim
mm
challa
et
al
potenc
cell
line
depend
yu
colleagu
report
identifi
novel
thienodiazepin
n
inhibitor
improv
potenc
broad
spectrum
activ
rsv
b
strain
although
also
cell
type
depend
compound
demonstr
direct
bind
recombin
n
fragment
surfac
plasmon
reson
spr
k
mm
xray
coecryst
structur
show
bind
site
overlap
nep
interact
site
mutat
residu
caus
reduc
inhibit
resist
ec
howev
affect
inhibitor
bind
n
protein
assess
spr
suggest
mechan
resist
may
due
reduc
inhibitoren
bind
dual
mechan
action
n
inhibitor
highlight
potenti
class
inhibitor
deliv
efficaci
suppress
resist
novel
broad
spectrum
antivir
influenza
block
dsrna
bind
protein
restor
antivir
respons
jiyoung
min
institut
pasteur
korea
influenza
viru
nonstructur
protein
known
antagonist
host
antivir
respons
small
molecul
name
boc
inhibit
human
season
b
virus
avian
subtyp
virus
dsrna
bind
pocket
protein
shown
put
target
base
vitro
dsrna
bind
assay
influenza
virusinfect
cell
show
increas
nfkb
nuclear
transloc
elev
level
variou
cytokin
relat
interferonstimul
gene
boc
administ
mice
infect
avian
influenza
viru
reduc
lung
viru
titer
earli
stage
infect
result
thu
suggest
boc
may
abrog
antagonist
respons
protein
current
nai
base
transit
state
analogu
dana
new
seri
compound
base
natur
substrat
sialic
acid
difluoro
sialic
acid
dfsa
recent
describ
kim
et
al
dfsa
requir
catalyt
activ
na
bind
henc
term
mechanismbas
inhibitor
form
coval
link
tyrosin
enzym
activ
site
unlik
nai
competit
inhibitor
efficaci
depend
slow
turnov
coval
link
inhibitor
substitut
sugar
ring
either
group
affect
affin
rate
bind
dissoci
ic
kinet
assay
barrett
et
al
even
strike
effect
orient
fluoro
group
equatori
potent
axial
dfsa
broad
efficaci
ic
enzym
assay
plaqu
reduct
assay
low
nm
mm
rang
protect
mice
lethal
influenza
infect
also
effect
virus
resist
oseltamivir
zanamivir
theoret
resist
dfsa
difficult
select
sinc
mutat
would
compromis
na
function
resist
virus
select
passag
influenza
b
viru
vitro
viru
reduc
almost
undetect
level
passag
lower
drug
concentr
howev
led
isol
small
plaqu
variant
viru
highli
resist
plaqu
reduct
assay
mutant
viru
bare
detect
enzym
activ
replic
compar
titer
vitro
wild
type
viru
preliminari
result
suggest
novel
mutat
na
remain
confirm
dfsa
also
activ
human
dirr
et
al
streltsov
et
al
sinc
na
human
mohr
et
al
hooper
et
al
virus
demonstr
receptor
bind
well
catalyt
function
recent
focu
antivir
target
ha
need
understand
secondari
role
na
may
compens
inhibit
ha
receptor
bind
function
may
need
target
ha
na
mario
pinto
nserc
ottawa
canada
addit
catalyt
site
group
na
amino
acid
form
loop
either
project
activ
site
close
conform
remain
outsid
activ
site
open
conform
creat
caviti
adabala
et
al
amaro
et
al
wang
et
al
pinto
colleagu
creat
carbocycl
analogu
zanamivir
replac
hydrophil
glycerol
side
chain
hydrophob
pentyloxi
group
oseltamivir
kerri
et
al
mohan
et
al
inhibitor
target
catalyt
site
show
nm
potenc
nai
assay
ki
nm
ki
zanamivir
nm
ec
nm
cell
cultur
activ
lower
oseltamivir
resist
mutant
fold
resist
appear
due
increas
flexibl
pendant
pentyloxi
group
abil
pivot
strong
hydrogenbond
network
howev
properti
suggest
would
still
suitabl
topic
applic
pinto
also
describ
seri
triazolecontain
carbocyl
relat
oseltamivir
bound
catalyt
site
caviti
adabala
et
al
amaro
et
al
mohan
et
al
wang
et
al
inhibit
viru
replic
vitro
triazol
deriv
contain
either
amino
guanidino
modif
indic
guanidinium
compound
higher
efficaci
subtyp
concentr
mm
inhibit
replic
subtyp
viru
even
concentr
mm
also
briefli
describ
serendipit
discoveri
potent
spirolactam
na
inhibitor
mohan
et
al
bindumadhav
marath
st
jude
chidren
research
hospit
memphi
usa
due
emerg
resist
oseltamivir
sever
group
investig
combin
therapeut
direct
differ
viru
target
oseltamivir
mgkg
mgkg
combin
two
administ
mice
h
postinfect
mice
protect
h
h
combin
gave
protect
h
singl
drug
surviv
rate
compar
combin
log
decreas
mous
lung
viru
titer
monotherapi
log
decreas
combin
therapi
analysi
lung
tissu
immunohistochemistri
histomorphometri
reveal
combin
therapi
restrict
viru
spread
reduc
extent
lesion
compar
monotherapi
combin
therapi
also
reduc
proinflammatori
cytokin
respons
reduc
diseas
sever
facilit
recoveri
masaktoki
sato
fukushima
medic
univers
japan
peramivir
rapivab
administ
singl
dose
iv
licens
japan
treatment
adult
children
infant
approv
usa
acut
uncompl
influenza
patient
year
older
studi
investig
pharmacokinet
peramivir
children
mean
serum
peramivir
concentr
among
children
h
mgkg
dose
mm
day
reduc
nm
respect
mean
concentr
urt
h
administr
mm
nm
day
drug
undetect
day
viral
rna
load
infect
decreas
day
day
increas
patient
day
decreas
viral
rna
load
much
less
influenza
b
influenza
resist
viru
detect
henc
singl
peramivir
dose
appear
inadequ
virolog
readministr
consid
sever
case
jun
wang
univers
arizona
tucson
usa
influenza
viru
bind
sialic
acid
receptor
taken
endosom
low
ph
activ
format
ion
channel
caus
influx
proton
virion
interior
result
dissoci
matrix
protein
viru
rnp
releas
cell
protein
highli
conserv
inhibit
adamantan
howev
resist
aris
rapidli
due
three
major
mutat
common
mutant
contract
channel
compar
wild
type
wt
hypothesis
pore
undergo
conform
chang
openclos
closedopen
h
goe
outsid
insid
guid
molecular
dynam
simul
nmr
xray
crystallographi
studi
group
develop
amantadin
deriv
effect
resist
mutant
wang
et
al
one
compound
contain
charg
ammonium
group
sit
insid
channel
plaqu
reduct
assay
ec
nm
mutant
comparison
nm
amantadin
wt
four
passag
drug
concentr
increas
nm
select
resist
mutant
howev
greater
increas
drug
concentr
nm
mm
select
resist
mutant
mutat
passag
revers
occur
decreas
bind
howev
limit
remain
new
compound
need
bind
wild
type
mutant
mutat
found
natur
avian
virus
isol
wild
bird
addit
influenza
b
virus
inhibit
aminoadamantan
influenza
viru
ha
protein
homotrim
monom
compos
two
disulfidelink
subunit
ha
bind
sialic
acid
receptor
cell
surfac
viru
taken
endosom
low
ph
lead
conform
chang
ha
trimer
fusogen
form
form
head
region
protein
primarili
involv
receptor
bind
wherea
refer
stem
region
involv
promot
virusehost
membran
fusion
variou
group
target
ha
tri
either
stabil
prefus
form
block
receptor
bind
site
antibodi
direct
head
region
appear
potent
wherea
direct
stalk
region
appear
broadli
reactiv
georg
gao
chines
academi
scienc
beje
china
gao
describ
discoveri
antistem
monoclon
antibodi
isol
convalesc
plasma
patient
infect
viru
wu
et
al
neutralis
group
virus
test
two
virus
surprisingli
group
influenza
virus
includ
two
two
inhibit
low
phinduc
hamedi
membran
fusion
heavi
light
chain
involv
bind
antibodi
crosslink
two
monom
trimer
antibodi
protect
infect
vitro
mice
second
antibodi
mab
deriv
virusinfect
patient
bind
near
receptor
bind
site
sit
helix
interact
partli
loop
head
ha
howev
specif
ha
sinc
region
conserv
megan
shaw
mount
sinai
hospit
new
york
usa
high
throughput
screen
use
recombin
influenza
viru
luciferas
gene
replac
ha
gene
cell
express
ha
luminesc
detect
whole
viru
produc
almost
compound
hit
rate
compound
show
dose
respons
effect
white
et
al
top
five
screen
wild
type
virus
three
show
influenza
specif
inhibit
broadli
reactiv
two
broadli
reactiv
react
subset
virus
show
reactiv
rna
dna
virus
suggest
host
cell
target
three
influenzaspecif
hit
broader
reactiv
interact
cterminu
np
react
nterminu
np
protein
react
ha
group
virus
influenza
b
virus
test
wild
type
viru
ic
nm
caus
maximum
reduct
viru
titer
log
low
toxic
cc
mm
time
addit
assay
use
hana
pseudotyp
hiv
particl
show
inhibit
entri
resist
virus
select
passag
vitro
mutat
affect
ha
primarili
around
b
loop
structur
connect
larg
small
helic
subunit
white
et
al
red
cell
fusion
assay
ph
fusion
fusion
ph
lower
ph
presenc
indic
stabilis
prefus
form
also
protect
ha
convers
trypsin
sensit
form
low
ph
condit
contrast
ph
fusion
mutant
unaffect
silico
dock
studi
predict
bind
stalk
region
correspond
area
resist
mutat
occur
merika
treant
univers
washington
seattl
usa
comput
design
engin
small
protein
amino
acid
protect
mice
weight
loss
death
administ
either
singl
prophylact
dose
h
prior
viru
challeng
h
postinfect
administ
daili
mgkg
synergist
respons
provid
full
protect
seen
suboptim
dose
oseltamivir
mgkg
determin
whether
immun
respons
develop
protein
mice
immunis
multipl
dose
challeng
viru
immun
respons
seen
mice
fulli
protect
ifng
increas
control
mice
lower
mice
correl
lower
viru
titer
rapid
recoveri
also
reduc
clinic
sign
influenzainfect
ferret
intraven
administr
could
detect
blood
henc
pharmacokinet
studi
use
inhal
administr
label
compound
appear
coat
respiratori
tract
seema
jasim
roslin
institut
royal
dick
school
veterinari
studi
univers
edinburgh
uk
approach
novel
antivir
compound
includ
develop
synthet
peptid
disrupt
entri
viru
cell
two
peptid
flupep
famili
short
hydrophob
peptid
relat
suppressor
cytokin
soc
protein
entri
blocker
deriv
signal
sequenc
fibroblast
growth
shown
antivir
activ
panel
virus
vitro
vivo
nicol
et
al
plaqu
reduct
assay
flupep
effect
although
lower
sensit
compar
viru
ic
rang
low
nm
nm
nicol
et
al
recombin
differ
sensit
depend
ha
entri
blocker
show
strain
specif
act
upstream
nuclear
import
rnp
peptid
caus
aggreg
fluoresc
label
viru
particl
surfac
host
cell
appear
slow
internalis
given
prophylact
mice
decreas
viru
titer
protect
weight
loss
oral
avail
rsv
inhibitor
target
fusion
protein
block
viru
envelop
fusion
host
cell
membran
devincenzo
et
al
mackman
et
al
highli
effect
rsv
b
mean
ec
nm
clinic
isol
rsv
nm
b
nm
low
toxic
si
block
rsv
attach
cell
interfer
viru
entri
cellecel
fusion
cellbas
fusion
inhibit
assay
ec
nm
resist
virus
isol
passag
vitro
mutat
f
protein
includ
rsv
confer
resist
rsv
b
crossresist
anoth
rsv
fusion
inhibitor
dougla
et
al
mckimmbreschkin
also
undergo
clinic
develop
inhal
product
cotton
rat
singl
ip
dose
mgkg
administ
h
prior
intranas
challeng
rsv
log
differ
seen
viru
rna
load
nasal
wash
lung
lavag
sampl
day
mgkg
group
small
trial
calv
infect
pfu
nebulis
bovin
rsv
treat
h
prior
infect
twice
daili
day
mgkg
nonsignific
decreas
viru
titer
signific
decreas
symptom
score
doubl
blind
placebocontrol
trial
carri
healthi
subject
experiment
infect
pfu
rsv
strain
nasal
wash
sampl
day
test
rsv
rtpcr
posit
day
whichev
sooner
subject
randomis
cohort
treat
follow
cohort
day
mg
day
mg
daili
cohort
day
mg
day
mg
daili
cohort
day
mg
cohort
day
mg
day
mg
daili
patient
treatment
group
show
signific
decreas
area
curv
auc
log
viru
load
vs
log
pfu
equival
lower
mucu
weight
day
first
dose
vs
g
p
lower
symptom
score
cohort
compar
result
although
cohort
show
decreas
mucu
weight
resist
frequenc
mutat
select
vitro
virus
show
decreas
fit
plan
test
higher
singl
dose
mg
tri
avoid
resist
john
devincenzo
univers
tennesse
memphi
usa
john
gave
overview
clinic
observ
correl
protect
higher
viru
load
nose
correspond
sever
diseas
faster
viru
clearanc
correl
faster
clinic
improv
detect
viru
mrna
rtpcr
correl
viru
rna
sensit
viru
cultur
rna
detect
often
day
although
gener
cultur
neg
day
iga
sampl
may
inhibit
viru
growth
lung
patholog
show
high
viru
stain
low
number
immun
cell
unlik
influenza
viru
peak
day
symptom
day
rsv
viru
load
symptom
peak
time
children
higher
viru
titer
shed
viru
longer
compar
adult
palivizumabmotavizumab
monoclon
antifus
antibodi
effect
prophylact
aapcid
show
clinic
efficaci
treatment
children
hospitalis
rsv
ramilo
et
al
differ
approach
alreadi
discuss
use
rnai
exampl
target
n
gene
devincenzo
et
al
trial
use
nasal
spray
administ
daili
day
day
rsv
inocul
show
antivir
activ
rsv
infect
proport
culturedefin
rsv
infect
placebo
recipi
respect
ronald
turner
univers
virginia
usa
current
antivir
agent
licens
treatment
rhinoviru
infect
common
cold
gener
selflimit
diseas
origin
target
broadli
effect
inhibitor
demonstr
addit
would
need
cheap
side
effect
interferon
proteas
inhibitor
capsid
bind
inhibitor
show
efficaci
laboratori
model
patient
hayden
although
rhinoviru
rv
import
caus
exacerb
copd
asthma
henc
altern
target
good
clinic
model
evalu
therapi
prophylaxi
may
feasibl
famili
studi
signific
decreas
asthma
score
pleconaril
prophylaxi
howev
approach
therapi
complic
discoveri
new
speci
rhinoviru
rvc
addit
known
rva
rvb
virus
palmenberg
gern
rvb
inher
resist
capsid
binder
differ
cellular
receptor
rva
rvb
instead
hostdirect
therapi
tlr
antagonist
probiot
may
promis
recent
studi
report
benefici
effect
probiot
lactobacillu
spp
occurr
common
cold
ill
children
ballenge
turner
sue
gerber
center
diseas
control
prevent
atlanta
usa
enteroviru
first
identifi
unlik
enterovirus
caus
febril
rash
neurolog
syndrom
commonli
associ
respiratori
ill
may
play
role
asthma
exacerb
summer
fall
larg
increas
sever
respiratori
ill
usa
cdc
state
health
laboratori
identifi
peopl
pcr
posit
midgley
et
al
howev
rhinoviru
coxsacki
viru
echovirus
also
detect
rhinovirusenteroviru
multiplex
pcr
use
sequenc
identifi
specimen
posit
sever
case
flaccid
myeliti
tempor
relat
infect
causal
role
establish
new
realtim
rtpcr
test
avail
cdc
zhuge
et
al
three
strain
identifi
belong
one
strain
second
singl
case
third
strain
viru
grow
mk
cell
human
lung
cell
bind
link
sialic
acid
sensit
pleconaril
capsid
bind
inhibitor
vitro
randomis
doubl
blind
placebo
control
trial
suggest
shorter
time
cultur
pcr
neg
statu
oral
pleconaril
remov
sialic
acid
receptor
also
evalu
abzug
et
al
mark
denison
vanderbilt
univers
nashvil
usa
coronavirus
cov
endem
respiratori
pathogen
caus
mainli
cold
bronchiol
pneumonia
addit
zoonot
transmiss
occur
sarscov
recent
merscov
larg
number
endogen
bat
cov
identifi
largest
genom
rna
viru
kb
three
proteas
proof
read
exonucleas
endonucleas
helicaseatpas
sar
exonminu
viru
appear
acquir
lethal
mutat
uracil
mutagen
treatment
wild
type
smith
et
al
also
attenu
mice
henc
high
replic
fidel
critic
cov
treatment
vitro
ribonucleosid
analogu
gilead
caus
log
reduct
viru
titer
compar
control
combin
fidel
inhibitor
nucleosid
analogu
may
provid
broad
activ
multipl
cov
thoma
voss
sri
intern
harrisonburg
virginia
usa
dipeptidyl
peptidas
receptor
merscov
multifunct
protein
target
diabet
therapi
apoptosi
cell
line
deriv
mink
lung
epithelium
suscept
infect
merscov
although
ferret
cell
express
base
antibodi
reactiv
ferret
infect
mink
challeng
merscov
show
sign
ill
viru
tissu
differ
challeng
rout
tri
intranas
oral
intratrach
intraocular
challeng
dose
differ
challeng
strain
includ
one
adapt
mink
lung
cell
altern
anim
model
normal
mice
suscept
merscov
express
human
overcom
lack
suscept
transgen
mice
develop
sever
lethal
respiratori
diseas
upon
inocul
merscov
potenti
suitabl
anim
model
efficaci
test
therapeut
prophylact
countermeasur
van
doremalen
munster
jeanfrancoi
rossignol
romark
laboratori
florida
usa
nitazoxanid
approv
treatment
diarrhoea
associ
giardia
cryptosporidium
infect
use
million
patient
usa
latin
america
alon
henc
known
safeti
profil
oral
avail
small
mw
drug
appear
broad
antivir
activ
includ
influenza
piv
rsv
nitazoxanid
appear
block
matur
influenza
viru
ha
rossignol
phase
trial
compar
mg
twice
daili
patient
treatment
mg
twice
daili
day
associ
reduct
durat
symptom
log
decreas
viru
titer
recipi
acut
uncompl
influenza
haffizulla
et
al
nitazoxanid
also
shown
synergist
effect
vitro
nai
belardo
et
al
current
phase
iii
trial
mg
nitazoxanid
compar
nitazoxanid
plu
oseltamivir
oseltamivir
placebo
wayn
marasco
harvard
medic
school
boston
usa
studi
respiratori
virus
group
use
nonimmun
human
antibodi
phage
display
librari
sourc
human
monoclon
antibodi
mab
complementari
strategi
use
singl
memori
b
cell
clone
isol
broadli
neutral
antibodi
isol
antibodi
sarscov
merscov
blood
sampl
obtain
china
arabia
binder
identifi
use
pseudotyp
virus
initi
sarscov
mab
neutralis
isol
interfer
glycoprotein
spike
bind
receptor
site
howev
virus
isol
patient
small
outbreak
resist
neutral
due
singl
aspgli
mutat
new
mab
made
cover
escap
mutant
sui
et
al
howev
recent
work
shown
even
two
mab
combin
prevent
emerg
escap
mutant
sui
et
al
merscov
emerg
arabian
peninsula
appear
endem
year
mani
camel
infect
includ
elit
race
camel
although
primari
host
may
bat
june
case
death
use
scfv
phage
librari
mab
encompass
three
differ
epitop
spike
identifi
inhibit
bind
receptor
spr
assay
escap
mutant
identifi
chang
five
amino
acid
critic
neutral
escap
loss
bind
one
epitop
major
impact
bind
ab
direct
epitop
mutant
reduc
fit
result
decreas
viru
amplif
reduc
inflamm
lung
infect
rhesu
monkey
screen
antibodi
influenza
identifi
mab
bound
common
epitop
ha
stem
prevent
postattach
fusion
process
sui
et
al
appear
use
variabl
heavi
chain
region
high
conserv
antibodi
protect
mice
decreas
viru
load
antibodi
crossreact
subgroup
influenza
subgroup
gener
escap
mutant
difficult
select
decreas
fit
mutat
outsid
epitop
caus
destabil
trimer
anoth
mab
broadli
activ
group
stabil
prefus
form
ha
assess
block
trypsin
cleavag
unexpectedli
despit
select
group
strain
efficaci
vitro
vivo
higher
group
virus
qing
zhu
medimmun
gaithersburg
usa
humanis
mab
synagi
palivizumab
still
mab
viral
diseas
approv
clinic
use
us
fda
wide
use
prevent
rsv
infect
neonat
immunocompromis
individu
human
polyclon
antibodi
prepar
also
use
prevent
rsv
signific
batch
variat
new
mab
higher
potenc
neutral
rsv
b
strain
ec
cotton
rat
model
mgml
compar
mgml
palivizumab
half
life
day
monkey
day
phase
trial
adult
human
aim
increas
half
life
enabl
singl
intramuscular
inject
effect
whole
season
thu
provid
vaccinelik
immun
anoth
mab
neutral
influenza
strain
bind
highli
conserv
epitop
ha
stalk
median
ic
mgml
multipl
effect
virusinduc
membran
fusion
ha
matur
cellecel
spread
claim
superior
oseltamivir
given
late
infect
mice
ferret
given
day
postinfect
mice
protect
versu
protect
oseltamivir
combin
oseltamivir
suboptim
dose
demonstr
synergist
effect
aim
gener
bispecif
antibodi
influenza
b
tatiana
baranovich
st
jude
children
research
hospit
memphi
usa
broadli
neutral
human
antiha
antibodi
react
region
ha
stalk
conserv
group
influenza
virus
tharakaraman
et
al
appear
lower
affin
ha
henc
efficaci
test
oseltamivirsuscept
resist
influenza
virus
mice
administ
via
intraperiton
inject
either
singl
mg
kg
dose
h
prophylaxi
mgkg
dose
h
treatment
viru
inocul
weight
loss
morbid
viru
lung
titer
monitor
prophylact
administr
antibodi
result
protect
mice
singl
ip
administr
mgkg
h
post
infect
also
provid
surviv
wherea
mgkg
dose
protect
anhuiinfect
shanghaiinfect
mice
dose
test
protect
mice
acut
respiratori
distress
syndrom
ard
dose
respons
number
cell
posit
np
mice
develop
antiha
immun
respons
suffici
provid
protect
mld
challeng
homolog
viru
antibodydepend
enhanc
ade
diseas
implic
therapeut
monoclon
antibodi
develop
sujan
shresta
la
jolla
institut
allergi
immunolog
la
jolla
usa
four
type
dengu
viru
denv
caus
million
case
million
sever
case
death
per
year
infect
rang
asymptomat
selflimit
febril
ill
dengu
fever
df
life
threaten
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
role
antibodi
cell
mediat
protect
versu
pathogenesi
remain
unclear
antibodydepend
enhanc
ade
identifi
year
ago
hypothesis
due
presenc
subneutr
level
antibodi
consequ
bind
antibodyco
viru
fc
receptor
fcr
facilit
viru
entri
lead
enhanc
infect
case
secondari
infect
matern
antibodi
newborn
may
crossreact
antibodi
insuffici
neutral
viru
model
dhfdsslike
diseas
develop
mice
lack
type
ifn
receptor
ifnar
ifngr
mous
model
reproduc
key
pathophysiolog
featur
dhfdss
includ
similar
cellular
tissu
tropism
lethal
vascular
leakag
cytokin
storm
low
platelet
count
elev
hematocrit
hemorrhag
tang
et
al
order
test
hypothesi
mice
pretreat
differ
level
antibodi
ip
follow
denv
challeng
mg
antibodi
low
effect
subneutr
dose
mg
led
sever
diseas
death
fulli
neutral
dose
mg
protect
mice
viru
load
significantli
higher
h
liver
ade
mice
compar
nonad
mice
import
interact
fc
denvab
complex
fcg
receptor
confirm
use
antibodi
mutant
fc
region
bind
fcg
receptor
fcg
receptorblock
antibodi
fab
fragment
antidenv
ab
intervent
could
decreas
enhanc
viru
titer
liver
ade
mice
nonad
level
anoth
model
use
vee
replicon
denv
protein
viru
replicon
particl
immunis
mice
higher
surviv
rate
lower
viru
titer
challeng
denv
zellweg
et
al
howev
passiv
transfer
ml
immun
sera
result
ade
recipi
mice
determin
role
cell
deplet
use
show
wherea
mice
low
viru
titer
deplet
mice
high
viru
titer
thu
cell
confer
greater
protect
mice
prime
uvirradi
dengu
viru
cell
protect
ade
thu
term
vaccin
develop
cellular
humor
immun
respons
need
induc
fcefcr
interact
control
surend
khurana
fda
bethesda
usa
influenza
pandem
sever
report
suggest
prior
vaccin
season
inactiv
influenza
vaccin
increas
sever
clinic
diseas
follow
infect
viru
skowronski
et
al
mechan
vaccineassoci
enhanc
respiratori
diseas
vaerd
well
understood
use
swine
model
khurana
et
al
show
vaccin
pig
viru
challeng
viru
result
pig
enhanc
pneumonia
diseas
use
recombin
express
spr
bind
assay
show
sera
react
viru
antibodi
bound
viru
compet
stemtarget
antibodi
sera
also
enhanc
infect
mdck
cell
promot
viru
fusion
activ
adsorpt
sera
effect
reduc
enhanc
effect
live
vaccin
pig
caus
ade
howev
administr
uvinactiv
vaccin
result
ade
find
studi
gener
concern
clinic
trial
evalu
univers
vaccin
monoclon
antibodi
therapeut
monitor
antibodyassoci
enhanc
diseas
manwah
tan
genentech
san
francisco
usa
human
monoclon
antibodi
bind
highli
conserv
region
ha
stalk
influenza
virus
trial
challeng
intraven
dose
test
mg
primari
end
point
decreas
viru
load
secondari
endpoint
decreas
clinic
symptom
mg
dose
one
decreas
viru
load
evid
ade
increas
diseas
sever
lower
dose
broadli
neutral
antibodi
influenza
characteris
potenti
ade
jose
trevejo
visterra
inc
cambridg
usa
investig
concern
ade
suboptim
antibodi
concentr
infect
cell
treat
low
medium
high
concentr
mab
enhanc
infect
seen
concentr
evalu
murin
macrophag
cell
line
treatment
na
remov
sialic
acid
receptor
result
decreas
infect
influenza
addit
increas
infect
fcefcr
bind
enhanc
infect
without
na
treatment
date
resist
seen
group
influenza
virus
mutat
abrog
bind
result
decreas
viru
fit
host
cell
target
factor
involv
viru
replic
mediat
inflammatori
respons
use
genet
approach
discov
hosteviru
interact
abe
brass
ragan
institut
massachusett
gener
hospit
usa
elucid
role
host
protein
rhinoviru
replic
three
set
commerci
rnai
pool
use
readout
base
number
cell
infect
redund
set
help
address
fals
posit
neg
inhibit
screen
gene
express
base
microarray
host
cell
transmembran
protein
rnasek
identifi
necessari
replic
multipl
hrv
serotyp
influenza
dengu
virus
perreira
et
al
rnasek
associ
vatpas
requir
endosom
acidif
endocytosi
sean
studer
scripp
research
institut
la
jolla
usa
sphingosin
pleiotrop
lysophospholipid
mediat
present
plasma
releas
larg
amount
activ
platelet
type
receptor
found
variou
type
cell
tissu
found
mostli
cell
immun
system
mostli
nervou
system
sphingosin
analogu
aalr
target
type
blunt
type
ifn
respons
cytokin
induct
upon
influenza
infect
mice
without
affect
antibodi
respons
marsolai
et
al
walsh
et
al
presenc
aalr
purifi
dendrit
cell
dc
spleen
lung
produc
lower
level
ifna
viru
infect
stimul
ifn
induc
cpg
also
mark
reduct
infiltr
pml
macrophag
lung
result
pulmonari
tissu
injuri
dc
matur
suppress
limit
prolifer
specif
antivir
cell
lung
drain
lymph
node
receptor
agonist
caus
similar
effect
broadlyact
aalr
walsh
et
al
howev
knockout
lethal
mice
ari
heleniu
eth
zurich
switzerland
endocytosi
uncoat
influenza
viru
core
occur
follow
twostep
prime
process
involv
influx
proton
k
ion
ion
channel
protein
induc
irrevers
conform
chang
protein
weaken
associ
stauffer
et
al
hamedi
membran
fusion
core
detach
endosom
surfac
vrnp
dissoci
cytosol
allow
vrnp
transport
nuclear
pore
nucleu
treatment
cell
importazol
importin
inhibitor
mutat
consensu
sequenc
transportin
bind
inhibit
postfus
transport
vrnp
use
sirna
silenc
cellular
target
hit
obtain
affect
uncoat
nuclear
import
knockdown
histon
deacetylas
essenti
compon
ubiquitindepend
aggresom
format
assembl
reduc
uncoat
banerje
et
al
bind
free
ubiquitin
cytosol
via
ctermin
zincfing
ubiquitinbind
domain
ubd
recruit
late
endosom
surfac
infect
capsid
mimic
misfold
protein
aggreg
bind
unanchor
ubiquitin
free
ubiquitin
also
found
viru
particl
associ
actin
myosin
microtubul
lead
physic
disrupt
endosom
core
structur
cleavag
ubd
caspas
prevent
viru
uncoat
thu
cellular
protein
offer
potenti
target
antivir
strategi
ronald
moss
ansun
biopharma
usa
recombin
sialidas
catalyt
domain
actinomyc
viscosu
link
amphiregulin
glycosaminoglycan
respiratori
epitheliumeanchor
domain
improv
cell
target
increas
halflif
administ
via
inhal
nebulis
sialidas
cleav
termin
sialic
acid
residu
glycan
surfac
respiratori
cell
thu
reduc
receptor
avail
bind
virus
influenza
parainfluenza
mice
administ
mgkgday
h
preto
h
postinfect
reduc
lethal
belser
et
al
mice
infect
either
oseltamivirsensit
resist
virus
mgkg
protect
death
marjuki
et
al
phase
iib
trial
patient
influenza
receiv
mg
daili
day
multidos
mg
singl
dose
placebo
moss
et
al
group
treat
show
signific
decreas
viru
load
h
multidos
group
show
signific
decreas
day
howev
differ
time
allevi
clinic
symptom
patient
primarili
immunocompromis
transplant
patient
treat
compassion
use
basi
decreas
viru
load
less
need
oxygen
four
pivinfect
children
waghmar
et
al
cystic
fibrosi
patient
infect
oseltamivirresist
influenza
viru
show
improv
silveira
et
al
hematopoiet
cell
transplant
htc
recipi
infect
piv
also
appear
benefit
chalkia
et
al
unpublish
result
shown
patient
decreas
viru
load
increas
surviv
phase
ii
trial
piv
pneumonia
immunocompromis
patient
current
underway
gener
appear
safe
patient
shown
elev
alkalin
phosphatas
level
transient
increas
liver
enzym
moss
et
al
system
immunogen
antibodi
induc
healthi
patient
zenilman
et
al
henc
unlik
use
system
also
undergo
particl
size
test
minimis
system
absorpt
kristen
bedard
kineta
inc
seattl
usa
novel
class
small
molecul
isoflavon
identifi
trigger
natur
immun
respons
target
innat
immun
transcript
factor
critic
first
respond
essenti
suppress
viru
replic
clear
infect
compound
select
caus
phosphoryl
induc
nuclear
transloc
bedard
et
al
enhanc
interferonstimul
gene
induct
sar
led
product
analogu
improv
ec
nm
lead
compound
influenza
b
caus
log
reduct
viru
titer
vitro
similarli
lead
compound
rsv
reduc
viru
titer
log
time
addit
studi
vitro
treatment
h
postinfect
reduc
viru
yield
inhibitor
also
act
synergist
proteas
inhibitor
hcv
influenza
mice
treatment
preto
h
postinfect
mgkg
decreas
lung
viru
titer
log
log
respect
pretreat
h
result
surviv
day
compar
lethal
control
compound
oral
avail
intranas
deliveri
superior
minimum
toxic
dose
greater
mgkg
patholog
offtarget
receptor
activ
genotox
cardiotox
potenti
potent
antiinfluenza
antiinflammatori
activ
verdinexor
select
inhibitor
nuclear
export
sine
across
broad
panel
influenza
strain
includ
avian
influenza
margaret
lee
karyopharm
therapeut
inc
newton
usa
verdinexor
target
nuclear
export
influenza
vrnp
infect
cell
mediat
exportin
interact
viral
nuclear
export
protein
bound
vrnp
silenc
result
reduc
influenza
viru
replic
perwitasari
et
al
verdinexor
bind
revers
cystein
bind
pocket
inhibit
vrnp
export
replic
vitro
variou
influenza
subtyp
includ
ic
nm
ic
nm
avian
ic
nm
highli
pathogen
avian
ic
nm
influenza
b
ic
nm
treatment
h
preto
h
postinfect
result
log
reduct
viru
titer
mice
infect
prophylaxi
mg
verdinexor
day
prior
infect
reduc
lung
viru
titer
delay
dose
andor
h
postinfect
reduc
lung
viru
titer
lung
patholog
verdinexor
treatment
also
lower
express
proinflammatori
cytokin
associ
influenza
viru
infect
g
ifn
tnfa
ferret
treatment
h
postinfect
day
result
approxim
log
reduct
viru
load
minim
toxic
phase
trial
verdinexor
plan
target
sirtuin
novel
viral
restrict
factor
limit
acquir
resist
lillian
chiang
forg
life
scienc
doylestown
usa
sirtuin
famili
seven
nad
depend
deacylas
known
regul
numer
cellular
function
includ
metabol
cell
cycl
longev
act
viru
restrict
factor
sinc
sirna
knockdown
sirtuin
increas
viru
growth
koyuncu
et
al
small
molecul
activ
sirtuin
block
vitro
replic
virus
includ
influenza
hcmv
adenoviru
polyomaviru
antivir
develop
base
dual
inhibit
sirt
activ
potent
inhibitor
ic
nm
simultan
inhibit
unexpectedli
result
decreas
influenza
viru
titer
appear
initi
regul
terrier
et
al
restor
inhibit
result
reactiv
thu
induc
apoptosi
specif
virusinfect
cell
compar
oseltamivir
novel
inhibitor
lead
enhanc
viru
clearanc
inhibitor
alreadi
clinic
trial
huntington
diseas
could
act
synergist
antivir
like
oseltamivir
repurpos
signal
transduct
inhibitor
fight
flu
e
updat
stephan
ludwig
univers
muenster
germani
penetr
cell
influenza
virus
control
variou
cell
signal
pathway
includ
receptor
tyrosin
kinas
involv
entryendocytosi
ikknfkb
rafmekerk
involv
rnp
export
sever
antimek
inhibitor
clinic
trial
cancer
therapi
investig
potenti
antivir
action
influenza
block
nuclear
export
lead
accumul
rnp
nucleu
influenzainfect
cell
shown
caus
decreas
lung
viru
titer
influenzainfect
mice
surviv
lethal
infect
droebner
et
al
mek
inhibitor
shown
act
synergist
oseltamivir
suboptim
dose
haasbach
et
al
raf
inhibitor
zelboraf
vemurafenib
shown
greater
efficaci
oseltamivir
infect
current
lasag
lysin
acetyl
salicyl
glycin
deriv
aspirin
first
molecul
target
host
intracellular
protein
nfkb
undergo
phase
ii
clinic
trial
treatment
sever
influenza
viru
infect
ludwig
et
al
eritoran
antagonist
effect
influenza
induc
diseas
jorg
blanco
sigmovir
biosystem
rockvil
usa
tolllik
receptor
signal
lead
lung
inflamm
influenzainfect
mice
mice
highli
refractori
influenza
induc
lethal
administr
igg
also
protect
wildtyp
mice
infect
lethal
dose
influenza
intraven
administr
mgday
eritoran
synthet
antagonist
day
postinfect
increas
surviv
mice
shirey
et
al
mice
show
reduc
lung
patholog
clinic
symptom
cytokin
gene
express
treatment
tenfold
less
eritoran
decreas
surviv
eritoran
efficaci
decreas
increas
viru
challeng
surviv
tcid
surviv
tcid
respect
mice
subsequ
challeng
surviv
indic
immun
respons
develop
despit
eritoran
treatment
cotton
rat
infect
nonadapt
influenza
virus
treat
eritoran
show
reduc
lung
patholog
lower
level
shirey
et
al
mice
lung
homogen
cotton
rat
blood
eritoran
treatment
influenza
infect
show
strong
reduct
concentr
high
mobil
group
protein
agonist
known
involv
system
inflamm
detect
drug
resist
influenza
current
statu
futur
direct
larisa
gubareva
center
diseas
control
prevent
atlanta
usa
detect
drug
resist
requir
knowledg
molecular
mechan
underli
resist
phenotyp
marker
resist
criteria
correl
laboratori
result
clinic
relev
resist
inhibitor
limit
number
mutat
known
correl
resist
cell
cultur
vivo
howev
nai
cell
cultur
sensit
alway
correl
reduc
inhibit
na
enzym
henc
enzymebas
assay
use
surrog
assay
monitor
influenza
viru
suscept
nai
expert
work
group
surveil
influenza
antivir
suscept
use
fold
increas
ic
compar
refer
ic
valu
indic
possibl
resist
reduc
inhibit
defin
influenza
virus
increas
ic
influenza
b
virus
increas
ic
highli
reduc
inhibit
defin
influenza
virus
increas
ic
influenza
b
virus
increas
ic
commerci
kit
includ
refer
virus
panel
resist
virus
avail
cdc
isirv
avg
major
limit
enzymebas
assay
virus
must
amplifi
cultur
test
may
result
select
resist
virus
well
de
novo
mutat
new
bioluminesc
assay
may
howev
allow
direct
assess
na
enzym
inhibit
clinic
sampl
variou
sequenc
method
use
identifi
na
substitut
includ
high
throughput
well
pyrosequenc
next
gener
sequenc
howev
sensit
method
allow
screen
known
resist
mutat
novel
mutat
requir
use
phenotyp
assay
correl
presenc
low
level
resist
viru
wild
type
viru
clinic
sampl
lack
clinic
effect
also
challeng
characteris
larg
cluster
influenza
viru
crossresist
oseltamivir
peramivir
influenza
season
emi
takashita
nation
institut
infecti
diseas
tokyo
japan
influenza
season
influenza
virus
japan
screen
substitut
na
protein
confer
crossresist
oseltamivir
peramivir
prior
main
influenza
season
isol
sapporohokkaido
mutat
takashita
et
al
phylogenet
analysi
suggest
clonal
expans
singl
mutant
viru
viru
replic
well
wild
type
viru
cell
cultur
ferret
transmit
effici
droplet
infect
virus
two
addit
substitut
na
known
increas
replic
transmiss
fit
howev
model
suggest
third
substitut
na
destabilis
mutant
na
structur
thu
allow
fitter
wild
type
compet
domin
strain
bruno
lina
univers
claud
bernard
lyon
franc
follow
naturallyoccur
oseltamivir
resist
global
observ
studi
influenza
resist
inform
studi
iri
initi
studi
emerg
nai
resist
clinic
cours
influenza
nonimmunocompromis
treat
untreat
patient
whitley
et
al
year
studi
includ
nonimmunocompromis
patient
year
old
year
includ
children
age
year
rtpcrposit
patient
infect
singl
influenza
strain
year
influenza
receiv
oseltamivir
monotherapi
within
h
symptom
onset
season
baselin
resist
detect
emerg
resist
treatment
detect
oseltamivirtr
influenza
patient
total
mostli
mix
genotyp
resist
isol
children
year
old
resist
increas
studi
period
within
rang
resist
virus
detect
either
substitut
virus
substitut
virus
day
patient
still
rtpcr
posit
although
symptom
resolv
day
alicia
fri
center
diseas
control
prevent
atlanta
usa
sever
us
guidanc
document
recommend
influenza
test
influenza
season
treatment
chang
test
result
includ
outpati
high
risk
influenza
complic
hospitalis
patient
acut
respiratori
ill
similarli
antivir
treatment
recommend
hospitalis
patient
outpati
high
risk
influenza
complic
suspect
confirm
influenza
provid
urg
wait
laboratori
confirm
reli
result
insensit
assay
begin
treatment
howev
sever
studi
suggest
insensit
rapid
influenza
diagnost
assay
ridt
commonli
use
outpati
inpati
set
provid
wait
ridt
result
begin
treatment
mani
new
sensit
molecular
diagnost
assay
commerci
avail
howev
sensit
assay
expens
sever
studi
suggest
empir
treatment
period
high
influenza
preval
may
costeffect
addit
work
need
optim
use
antivir
treatment
vulner
popul
role
new
diagnost
assay
yet
determin
peter
miel
fda
silver
spring
usa
fda
guidanc
develop
drug
treatment
andor
prophylaxi
influenza
reflect
experi
previou
influenza
drug
develop
particip
work
group
fda
well
control
phase
efficaci
trial
necessari
support
fda
approv
influenza
antivir
studi
type
eg
human
challeng
studi
trial
special
popul
contribut
develop
clinic
trial
substitut
efficaci
trial
seriou
influenza
hospitalis
patient
face
sever
challeng
includ
heterogen
popul
medic
current
standard
care
vari
local
practic
current
product
proven
efficaci
would
allow
inferior
trial
valid
clinic
endpoint
accept
biomark
efficaci
endpoint
standardis
type
influenza
trial
trial
warrant
examin
multipl
secondari
endpoint
virolog
endpoint
eg
viru
shed
import
secondari
endpoint
primari
endpoint
fda
encourag
develop
novel
efficaci
endpoint
trial
treatment
seriou
influenza
conduct
pilot
studi
enter
phase
trial
endpoint
demonstr
improv
patient
feel
function
surviv
earli
discuss
fda
facilit
new
drug
develop
human
respiratori
viru
challeng
model
worthwhil
challeng
matthew
memoli
niaid
bethesda
usa
human
challeng
model
tool
help
describ
natur
histori
pathogenesi
influenza
virus
includ
viru
replic
shed
immun
respons
addit
human
challeng
model
inform
potenti
benefit
new
diagnost
vaccin
therapeut
new
model
recent
develop
genet
modifi
viru
memoli
et
al
challeng
studi
enrol
particip
hai
titer
demonstr
clinic
symptom
infect
antibodi
respons
correl
infect
dose
number
sever
symptom
correl
viral
shed
baselin
ha
na
antibodi
titer
invers
correl
diseas
sever
model
potenti
facilit
futur
studi
influenza
pathogenesi
anim
model
valid
evalu
novel
vaccin
therapeut
futur
model
includ
genet
modifi
b
virus
anthoni
gilbert
retroscreen
hvivo
london
uk
retroscreen
carri
trial
last
patient
per
trial
volunt
trial
randomis
doubl
blind
placebo
control
particip
age
virus
test
includ
rsv
hrv
influenza
primari
endpoint
tend
decreas
viru
load
rtpcr
cell
cultur
design
conduct
drug
develop
program
severecompl
influenza
lesson
iv
zanamivir
experi
amanda
peppercorn
glaxosmithklin
north
carolina
usa
challeng
conduct
phase
iii
studi
evalu
efficaci
intraven
iv
zanamivir
hospitalis
patient
includ
lack
valid
clinic
endpoint
inabl
placebo
arm
oseltamivir
compar
inabl
use
noninferior
design
sinc
randomis
trial
oseltamivir
licensur
perform
outpati
phase
iii
multisit
randomis
doubleblind
studi
compar
two
dose
iv
zanamivir
mg
mg
daili
oral
oseltamivir
mg
twice
daili
hospitalis
patient
age
year
confirm
influenza
symptom
onset
within
day
primari
endpoint
includ
hospit
discharg
sign
clinic
respons
afebril
satur
plu
two
follow
return
baselin
oxygen
need
respiratori
rate
puls
systol
blood
pressur
mm
hg
secondari
endpoint
includ
mortal
time
premorbid
function
statu
length
intens
care
unit
hospit
stay
sever
measur
virolog
improv
enrol
began
januari
complet
march
analysi
ongo
target
enrol
interim
analysi
particip
demonstr
particip
underli
medic
condit
symptom
day
less
enrol
among
influenzaposit
particip
median
day
clinic
respons
rang
day
time
improv
respiratori
statu
rang
day
addit
clinic
trial
glaxosmithklin
made
iv
zanamivir
avail
compassion
use
worldwid
approxim
treatment
cours
given
compassion
use
countri
affect
enrol
clinic
trial
challeng
design
inform
clinic
trial
patient
hospit
influenza
peramivir
experi
sylvia
dobo
biocryst
durham
usa
studi
iv
peramivir
mg
daili
compar
placebo
primari
endpoint
time
clinic
resolut
normal
temperatur
puls
respiratori
rate
systol
blood
pressur
oxygen
satur
subject
enrol
laboratoryconfirm
influenza
infect
howev
subject
receiv
oseltamivir
part
standard
care
exclud
analysi
thu
influenza
infect
particip
qualifi
primari
efficaci
analysi
placebo
peramivir
posit
viru
titer
baselin
symptom
h
also
inclus
oseltamivir
standard
care
often
use
patient
clinic
serious
ill
thu
patient
includ
final
analysi
less
ill
may
repres
sever
influenza
admit
optim
time
nai
effect
studi
termin
earli
deem
unlik
enrol
adequ
number
experi
trial
highlight
sever
roadblock
conduct
clinic
trial
new
antivir
drug
hospitalis
patient
widespread
avail
use
oseltamivir
obfusc
abil
randomli
alloc
placebo
group
reason
hospit
vari
hospit
per
se
may
appropri
case
definit
sever
diseas
hospitalis
patient
repres
continuum
diseas
lack
valid
endpoint
mani
variabl
could
contribut
resolut
endpoint
use
peramivir
studi
conduct
clinic
trial
hospitalis
patient
influenza
thu
present
uniqu
research
difficulti
futur
studi
might
improv
enrol
limit
patient
document
sever
ill
lower
respiratori
tract
ill
manwah
tan
genentech
san
francisco
usa
nai
enzym
assay
consist
demonstr
higher
ic
current
nai
influenza
b
virus
burnham
et
al
clinic
implic
unclear
observ
studi
suggest
slower
resolut
fever
oseltamivirtr
patient
influenza
b
infect
compar
patient
influenza
infect
human
monoclon
antibodi
influenza
b
ha
demonstr
block
membran
fusion
viru
attach
protect
mice
lethal
influenza
b
infect
michael
wathen
barda
washington
usa
barda
mission
develop
provid
countermeasur
cbrn
threat
pandem
influenza
emerg
infecti
diseas
product
develop
stockpil
acquisitionbuild
manufactur
infrastructur
build
product
innov
drug
develop
expens
lengthi
riski
product
make
stage
human
studi
fewer
phase
iii
trial
barda
antivir
program
includ
develop
two
nai
iv
peramivir
inhal
long
act
laninamivir
inhal
recombin
sialidas
fludas
broad
spectrum
hosttarget
small
molecul
nitazoxanid
futur
fund
shift
focu
unmet
medic
need
includ
emerg
antivir
resist
current
drug
treatment
sever
ill
patient
drug
wider
treatment
window
discoveri
develop
broadlyneutr
antibodi
sever
fund
announc
focuss
unmet
need
publish
addit
barda
conven
interag
work
group
develop
better
clinic
endpoint
sever
influenza
improv
studi
design
clinic
trial
john
devincenzo
univers
tennesse
memphi
usa
rsv
infect
common
result
estim
million
hospit
admiss
global
among
children
year
age
nair
et
al
effect
therapeut
rsv
current
licens
simo
et
al
novel
therapeut
develop
challeng
relat
evalu
new
agent
sever
rsv
diseas
discuss
rsvinfect
children
hospitalis
admit
later
ill
mean
day
thu
might
outsid
optim
therapeut
window
drug
studi
includ
telephon
survey
parent
suggest
parent
recognis
difficulti
breath
elev
respiratori
rate
wheez
sign
lower
respiratori
ill
earli
rsv
infect
approxim
children
taken
medic
care
within
day
ill
onset
within
day
ill
onset
thu
studi
evalu
new
therapeut
target
ambulatori
patient
may
feasibl
prevent
hospit
could
clinic
outcom
new
antiinfluenza
therapeut
agent
could
improv
morbid
associ
influenza
especi
target
treatment
sever
influenza
wider
therapeut
window
h
sever
novel
agent
potenti
add
current
armamentarium
influenza
describ
addit
studi
respiratori
virus
present
includ
target
protein
involv
replic
receptor
bind
fusion
host
cell
target
differ
phase
develop
made
human
studi
futur
challeng
includ
identifi
best
method
evalu
efficaci
sever
influenza
respiratori
diseas
monitor
advers
effect
relat
antibodi
